Literature DB >> 22273735

Antipsychotics and mortality in Parkinsonism.

Connie Marras1, Andrea Gruneir, Xuesong Wang, Hadas Fischer, Sudeep S Gill, Nathan Herrmann, Geoffrey M Anderson, Christopher Hyson, Paula A Rochon.   

Abstract

BACKGROUND: : The use of antipsychotic medications is associated with an increased risk of death in older adults with dementia. The risk of death in patients with preexisting parkinsonism who receive antipsychotic drugs is not known.
METHODS: : Using a nested case-control design, we examined the risk of death within 30 days of newly starting antipsychotic medications among people with Parkinsonism aged 70 years and older in Ontario, Canada. Data were obtained from Ontario's healthcare administrative databases.
RESULTS: : Among 5,391 individuals with parkinsonism who died during the study period (2002-2008) and a matched comparison group of 25,937 who were still alive, individuals exposed to atypical antipsychotic drugs had a higher risk of death (unadjusted odds ratio [OR] = 2.8, 95% CI: 2.1-3.8, adjusted OR: 2.0, 95% CI: 1.4-2.7). Results were similar for quetiapine use compared with no antipsychotic use (unadjusted OR: 2.5, 95% CI: 1.6-4.0, adjusted OR = 1.8, 95% CI: 1.1-3.0). Typical antipsychotics were associated with an increased odds of death compared with atypical antipsychotics (unadjusted OR = 2.4, 95% CI 1.1-5.2, adjusted OR = 2.4, 95% CI: 1.1-5.7).
CONCLUSIONS: : Individuals with parkinsonism who are newly prescribed antipsychotic medications have a higher risk of death within 30 days than those who do not start these medications. Although it is not possible to establish causality, the results suggest an increased risk. It is important to be vigilant for accompanying serious medical conditions that may increase mortality in individuals requiring treatment with antipsychotics and to consider alternative approaches to treating psychosis, agitation, and aggression in this population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22273735     DOI: 10.1097/JGP.0b013e3182051bd6

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  8 in total

1.  Prevalence of and indications for antipsychotic use in Parkinson's disease.

Authors:  James H Bower; Brandon R Grossardt; Walter A Rocca; Rodolfo Savica
Journal:  Mov Disord       Date:  2017-12-26       Impact factor: 10.338

Review 2.  Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Authors:  Kentaro Hirao; Gregory M Pontone; Gwenn S Smith
Journal:  Neurosci Biobehav Rev       Date:  2014-11-20       Impact factor: 8.989

3.  Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis.

Authors:  Kimberley Ruxton; Richard J Woodman; Arduino A Mangoni
Journal:  Br J Clin Pharmacol       Date:  2015-05-20       Impact factor: 4.335

4.  Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

Authors:  Daniel Weintraub; Claire Chiang; Hyungjin Myra Kim; Jayne Wilkinson; Connie Marras; Barbara Stanislawski; Eugenia Mamikonyan; Helen C Kales
Journal:  JAMA Neurol       Date:  2016-05-01       Impact factor: 18.302

5.  Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study.

Authors:  Nathan Herrmann; Connie Marras; Hadas D Fischer; Xuesong Wang; Geoff M Anderson; Paula A Rochon
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

6.  Trends and Contributing Factors for Prescribing Antipsychotics in Newly Diagnosed Parkinson's Disease Patients: A Population-Based Study.

Authors:  Khalid Orayj
Journal:  Risk Manag Healthc Policy       Date:  2021-06-04

Review 7.  The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease.

Authors:  Nevena Divac; Radan Stojanović; Katarina Savić Vujović; Branislava Medić; Aleksandar Damjanović; Milica Prostran
Journal:  Behav Neurol       Date:  2016-07-18       Impact factor: 3.342

8.  Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study.

Authors:  Poul Jennum; Lone Baandrup; Helle K Iversen; Rikke Ibsen; Jakob Kjellberg
Journal:  BMJ Open       Date:  2016-03-08       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.